HomeESPR • NASDAQ
Esperion Therapeutics Inc
add
$2.53
4.12%
After Hours:(0.33%)+0.0084
$2.54
Closed: Sep 4, 8:00:00 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 82.39M | 11.58% |
Operating expense | 39.51M | -10.58% |
Net income | -12.73M | 79.45% |
Net profit margin | -15.45 | 81.58% |
Earnings per share | -0.02 | 56.55% |
EBITDA | 7.12M | 175.62% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 86.06M | -54.54% |
Total assets | 347.09M | -1.49% |
Total liabilities | 780.59M | 12.07% |
Total equity | -433.51M | — |
Shares outstanding | 201.62M | — |
Price to book | -1.12 | — |
Return on assets | 5.29% | — |
Return on capital | 10.67% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -12.73M | 79.45% |
Cash from operations | -31.42M | -336.11% |
Cash from investing | — | — |
Cash from financing | 2.85M | 109.49% |
Net change in cash | -28.57M | 23.41% |
Free cash flow | -38.50M | -4,144.05% |
Previous close
$2.43
Day range
$2.40 - $2.58
Year range
$0.69 - $3.94
Market cap
510.11M USD
Avg Volume
6.34M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Website
Employees
304
